期刊文献+

侵袭性B细胞淋巴瘤新的标准治疗方案 被引量:3

New standard treatment for aggressive non-Hodgkin's lymphoma
下载PDF
导出
摘要 实施CHOP方案(环磷酰胺、阿霉素、长春新碱和泼尼松)治疗20多年来。侵袭性B细胞淋巴瘤已成为可治愈的疾病,CHOP方案也已成为治疗这一疾病的标准方案。但其治愈率只有35%-40%,半数以上复发。随着抗B细胞表面抗原CD20的人鼠嵌合型单克隆抗体利妥昔(rituximab)的应用,侵袭性B细胞淋巴瘤的治疗已发生了根本改变。多项大型Ⅲ期随机临床研究结果证实,利妥昔与CHOP方案或CHOP样方案联合应用,比单纯联合化疗能明显改善侵袭性B细胞淋巴瘤的有效率,无事件生存和长期生存结果,无论是老年或年轻患者,低危预后还是高危预后患者,均有显著的统计学差异。因此,利妥昔加CHOP或CHOP样方案的联合治疗已成为侵袭性B细胞淋巴瘤新的标准治疗方案。 Abstract Diffuse large B - cell lymphoma (DLBCL) is the most common type of aggressive non -Hodgkin's lymphomas (NHL). In the past more than two decades, CHOP chemotherapy (cyclophosphanide, doxorubin, vincreastine, prednisone ) had been the gold standard treatment for aggressive non- Hodgkin's lymphoma (NHL). CHOP is only curative in approximately 35 % - 45 % of patients with DLBCL, therefore improved treatment are required. But so far, attempts to improved on CHOP chemotherapy had been unsuccessful. However, The chimeric anti - CD20 monoclonal antibody rituximab combination with CHOP or CHOP- like immunochemotherapy has now emerged as a new standard first - line treatment for patients with aggressive NHL, on the basis of significantly improved event - free and overall survival observed in the GELA LNH 98.5 study in elderly patients and the Mabthera International Trial evaluating R- CHOP versus (or CHOP - like chemotherapy) in young patients with aggressive NHL and DSHNHL1999 - 2001 RICOVER60 study.
作者 周立强
出处 《癌症进展》 2006年第5期398-401,397,共5页 Oncology Progress
关键词 侵袭性淋巴瘤 弥漫大B细胞淋巴瘤 药物治疗 利妥昔 aggressive non- Hodgkin's lymphoma diffuse large B- cell lymphoma drug therapy rituximab
  • 相关文献

参考文献17

  • 1[1]Jaffe ES,Harris NL,Stein H,et al.World Health Organization Classification of tumors.Pathology and genetics of tumours of haematopoietic and lymphoid tissues.Lyon,France:IARC Press,2001
  • 2[2]DeVita VT Jr,Canellos GP,Chabner B,et al.Advanced diffuse histiocytic lymphoma:A potentially curable disease,Lancet,1975,1:248
  • 3[3]Fisher RI,Gaynor ER,Dahlberg S,et al.Comparison of a standar regimem (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.N Engl J Med,1993,328:1002
  • 4[4]Linch DC,Vaughan Hudson B,Hancock BW,et al.A randomized comparison of a third-generation regimen (PACEBOM)with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma:A British National Lymphoma Investigation report.Br J Cancer,1996,74:318
  • 5[5]Pfreundschuh M,Truemper L,Kloess M,et al.2-weekly vs 3-weekly CHOP with and without etoposide for patients > 60 years of age with aggressive non-Hodgkin's lymphoma (NHL):Results of the completed NHL-B-2 trial of the DSHNHL.Blood,2004,104:634
  • 6[6]Tilly H,Lepage E,Coiffer B,et al.Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin's lymphoma.Blood,2003,102:4284
  • 7[8]Coiffier B,Haioun C,Ketterer N,et al.Rituximab (antiCD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma:A multicenter phase Ⅱ study.Blood,1998,92:1927
  • 8[9]Vose JM,Link BK,Grossbard ML,et al.Phase Ⅱ study of rituximab in combination with CHOP chemotherapy in patients with previously untreated,aggressive non-Hodgkin's lymphoma.J Clin Oncol,2001,19:389
  • 9[10]Vose JM,Link BK,Grossbard ML,et al.Long term follow-up of a phase Ⅱ study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin's lymphoma (NHL).Blood,2002,100:36A
  • 10[11]Sehn LH,Jane Donaldson J,Chhanabhai M,et al.Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.J Clin Oncol,2005,23:5027

同被引文献30

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部